The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...

Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

Here’s what most pharma professionals don’t want to hear: if you're a scientist or physician who spent your career in pharma, ...

The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...

GLP-1 receptor agonists have captured global attention for their ability to drive weight loss and improve metabolic health.

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – ...

And with that increasing complexity come rising costs and the risk of delays that can slow the delivery of critical medicines to patients awaiting treatments – and flatten drug sponsors’ return on ...

The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...